Inhibition of TAK1 and/or JAK Can Rescue Impaired Chondrogenic Differentiation of Human Mesenchymal Stem Cells in Osteoarthritis-Like Conditions

Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve-month data from a twenty-four-month phase III randomized radiographic study

(2013) Désirée van der Heijde et al.   ARTHRITIS AND RHEUMATISM

TGF-β-activated Kinase 1 (Tak1) Mediates Agonist-induced Smad Activation and Linker Region Phosphorylation in Embryonic Craniofacial Neural Crest-derived Cells

(2013) Kenji Yumoto et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial

(2013) Gerd R Burmester et al.   LANCET

Targeting of TAK1 in inflammatory disorders and cancer

(2012) Hiroaki Sakurai   TRENDS IN PHARMACOLOGICAL SCIENCES

Chondrogenic differentiation of human subchondral progenitor cells is affected by synovial fluid from donors with osteoarthritis or rheumatoid arthritis

(2012) Jan Krüger et al.   Journal of Orthopaedic Surgery and Research

Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550)

(2011) Kamran Ghoreschi et al.   JOURNAL OF IMMUNOLOGY

Catabolic Factors and Osteoarthritis-Conditioned Medium Inhibit Chondrogenesis of Human Mesenchymal Stem Cells

(2011) Genoveva T.H. Heldens et al.   TISSUE ENGINEERING PART A

Cytokine-induced increases in ADAMTS-4 messenger RNA expression do not lead to increased aggrecanase activity in ADAMTS-5-deficient mice

(2010) Fraser M. Rogerson et al.   ARTHRITIS AND RHEUMATISM

TAK1 regulates cartilage and joint development via the MAPK and BMP signaling pathways

(2010) Lea M Gunnell et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Biology and pathology of Rho GTPase, PI-3 kinase-Akt, and MAP kinase signaling pathways in chondrocytes

(2010) Frank Beier et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis

(2010) Debra M Meyer et al.   Journal of Inflammation-London